Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2944876 · 1 trial · 1 indication
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Arm | Type | Description |
|---|---|---|
| 10 mg LY2944876 | EXPERIMENTAL | 10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| 15 mg LY2944876 | EXPERIMENTAL | 15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| 30 mg LY2944876 | EXPERIMENTAL | 30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| 50 mg LY2944876 | EXPERIMENTAL | 50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| Exenatide extended-release | EXPERIMENTAL | 2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| Placebo | PLACEBO_COMPARATOR | Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. |
| Name | Type | Description |
|---|---|---|
| LY2944876 | DRUG | Administered SC |
| Exenatide extended-release | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Metformin | DRUG | Oral |
Inclusion Criteria: * Men or women with diabetes mellitus Type 2 * Have screening HbA1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for 3 months prior to screening * Have body mass index (BMI) ≥23 and ≤45 kilograms per meter squared at screenin...
LY2944876 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
LY2944876 is being developed by Opko Health Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OPK. The drug is in Phase 2 clinical trials for Type 2 Diabetes Mellitus.
LY2944876 is in Phase 2 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not yet received regulatory approval.
LY2944876 has one completed Phase 2 clinical trial, identified as NCT02119819. This randomized, double-blind, placebo-controlled study enrolled 420 participants with Type 2 Diabetes Mellitus across the United States, Greece, Mexico, Poland, Puerto Rico, and Romania.
LY2944876 is the primary identifier for this investigational compound. No alternative names have been reported for this drug in its clinical development program.